- Home
- AVIR vs ABEO Comparison
AVIR vs ABEO Comparison
Compare AVIR & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- ABEO
- Stock Information
- Founded
- AVIR 2012
- ABEO 1974
- Country
- AVIR United States
- ABEO United States
- Employees
- AVIR N/A
- ABEO N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- ABEO Health Care
- Exchange
- AVIR Nasdaq
- ABEO Nasdaq
- Market Cap
- AVIR 273.0M
- ABEO 256.9M
- IPO Year
- AVIR 2020
- ABEO 1980
- Fundamental
- Price
- AVIR $3.73
- ABEO $5.69
- Analyst Decision
- AVIR Hold
- ABEO Strong Buy
- Analyst Count
- AVIR 1
- ABEO 6
- Target Price
- AVIR $6.00
- ABEO $18.00
- AVG Volume (30 Days)
- AVIR 407.1K
- ABEO 1.1M
- Earning Date
- AVIR 08-06-2025
- ABEO 08-11-2025
- Dividend Yield
- AVIR N/A
- ABEO N/A
- EPS Growth
- AVIR N/A
- ABEO N/A
- EPS
- AVIR N/A
- ABEO N/A
- Revenue
- AVIR N/A
- ABEO N/A
- Revenue This Year
- AVIR N/A
- ABEO N/A
- Revenue Next Year
- AVIR N/A
- ABEO $323.51
- P/E Ratio
- AVIR N/A
- ABEO N/A
- Revenue Growth
- AVIR N/A
- ABEO N/A
- 52 Week Low
- AVIR $2.46
- ABEO $3.93
- 52 Week High
- AVIR $4.15
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- AVIR 74.60
- ABEO 47.54
- Support Level
- AVIR $3.63
- ABEO $5.68
- Resistance Level
- AVIR $3.78
- ABEO $5.93
- Average True Range (ATR)
- AVIR 0.14
- ABEO 0.26
- MACD
- AVIR 0.02
- ABEO -0.01
- Stochastic Oscillator
- AVIR 100.00
- ABEO 56.25
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.